KOD
Kodiak Sciences Inc.
NASDAQ · USHealthcareBiotechnology
$40.87-4.15%
Price as of Jul 20, 2026
KOD financials
Kodiak Sciences Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $26.7M | $25.9M | $11.0M |
| Gross profit | $0.00 | -$26.7M | -$25.9M | -$11.0M |
| Operating expenses | $234.4M | $160.1M | $251.4M | $330.4M |
| Operating income | -$234.4M | -$186.8M | -$277.3M | -$341.4M |
| Net income | -$230.0M | -$176.2M | -$260.5M | -$333.8M |
| EBITDA | -$203.6M | -$149.5M | -$234.5M | -$322.8M |
| Basic EPS | $-4.32 | $-3.35 | $-4.97 | $-6.39 |
| Diluted EPS | $-4.32 | $-3.35 | $-4.97 | $-6.39 |
| Balance sheet | ||||
| Cash & equivalents | $209.9M | $168.1M | $285.5M | $190.4M |
| Total assets | $351.5M | $335.6M | $479.4M | $666.6M |
| Total liabilities | $194.2M | $185.3M | $213.6M | $230.5M |
| Stockholders’ equity | $157.4M | $150.3M | $265.8M | $436.2M |
| Total debt | $159.2M | $70.3M | $181.6M | $187.7M |
| Net debt | -$50.7M | -$97.7M | -$103.9M | -$2.7M |
| Cash flow | ||||
| Operating cash flow | -$136.0M | -$117.3M | -$154.2M | -$206.5M |
| Capital expenditure | -$506.0K | -$400.0K | -$41.4M | -$47.4M |
| Free cash flow | -$136.5M | -$117.7M | -$195.6M | -$253.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |